This product review focusses on the use of Atezolizumab for the treatment of non-small cell lung cancer.
The review discusses the evidence in support of the use of Atezolizumab, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Associate Professor Nick Pavlakis, a senior staff medical oncologist based at Royal North Shore Hospital and Genesis Care.
Please login below to download this issue (PDF)